| 2.77 0.05 (1.84%) | 05-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.37 | 1-year : | 3.79 |
| Resists | First : | 2.88 | Second : | 3.25 |
| Pivot price | 2.72 |
|||
| Supports | First : | 2.29 | Second : | 1.91 |
| MAs | MA(5) : | 2.76  |
MA(20) : | 2.71 |
| MA(100) : | 2.89 |
MA(250) : | 3.35 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 39.9 |
D(3) : | 39.4 |
| RSI | RSI(14): 52.1 |
|||
| 52-week | High : | 4.74 | Low : | 2.29 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PYPD ] has closed below upper band by 38.1%. Bollinger Bands are 39.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.8 - 2.82 | 2.82 - 2.83 |
| Low: | 2.74 - 2.75 | 2.75 - 2.77 |
| Close: | 2.75 - 2.77 | 2.77 - 2.79 |
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Tue, 29 Apr 2025
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 - TradingView
Tue, 29 Apr 2025
PolyPid Q1 2025 Earnings Preview: Surgical Outcomes Biopharma Reports May 14 - Stock Titan
Tue, 22 Apr 2025
PolyPid to Participate in The Citizens Life Sciences Conference - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 4.59e+006 (%) |
| Held by Institutions | 25 (%) |
| Shares Short | 3 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.641e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -86.4 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 30.73 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.09 |
| Price to Cash Flow | 4.65 |
| Dividend | 0 |
| Forward Dividend | 3900 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|